Health Care · Biological Products, (No Diagnostic Substances) · Nasdaq · CIK 1815776 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $5.72Day −2.72%Mkt cap $179M1Y −81.9%Off 52W high −88.7%Vol (1Y) 81.8%
Daily closing price, split-adjusted to the current basis; 2.3y shown of 586 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest37.8% of sh out |
| Days to cover10.5d |
| 13F net flow (QoQ)+4.60% |
| Top-10 13F concentration65.9% |
| Next report (est.)2026-08-10 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$19.1M |
| Earnings (TTM)-$109.0M |
| ROE−33.6% |
| Net margin−430.3% |
| ROIC−32.5% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−64.3% |
| 1Y−81.9% |
| Since incept. (ann.)−35.8% |
Total return through 2026-07-29 · series begins 2024-03-22. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)81.8% |
| Ann. volatility (3Y)77.0% |
| Sharpe (1Y)−1.68 |
| Sharpe (3Y)−0.19 |
| Max drawdown (1Y)−90.1% |
| Max drawdown (3Y)−90.1% |
| Beta (3Y vs SPY)1.52 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 4.2M | $38M | 13.33% | +0.0% |
| Alpha Wave Global, LP | 3.6M | $33M | 11.52% | +0.0% |
| FMR LLC | 3.6M | $33M | 11.47% | −2.8% |
| Versant Venture Management, LLC | 2.7M | $24M | 8.47% | +0.0% |
| BlackRock, Inc. | 2.0M | $18M | 6.30% | +16.8% |
| Squarepoint Ops LLC | 1.5M | $14M | 4.80% | +206.3% |
| Aberdeen Group plc | 1.2M | $11M | 3.69% | +136.2% |
| FRANKLIN RESOURCES INC | 1.1M | $10M | 3.51% | +0.3% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total. Institutional 13F holdings sum to 105.7% of shares outstanding. Readings above 100% reflect securities-lending double counting: shares on loan to short sellers are reported long by both the lending institution and the one that bought them. FINRA short interest of 10,723,872 shares (settlement 2026-04-30) accounts for the excess.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-11 | −$1.32 | — | $1.9M | — |
| 2025-09-30 | 2025-11-05 | −$0.59 | — | $12.5M | — |
| 2025-06-30 | 2025-07-30 | −$0.53 | — | $5.0M | — |
| 2025-03-31 | 2025-05-07 | −$0.53 | — | $0 | — |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-10 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
Reportable 100%
business segments · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
